Thomas R. Staab II - 11 May 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Reporting relationship: Chief Financial Officer
Issuer ticker: TENX
Reported as of: 11 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2026, 17:08:07 UTC
Prior SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: /s/ S. Halle Vakani, as Attorney-in-Fact

Key filing fact

Thomas R. Staab II filed Form 4 for TENAX THERAPEUTICS, INC. (TENX) on 13 May 2026.

Key facts

This page summarizes Thomas R. Staab II's Form 4 filing for TENAX THERAPEUTICS, INC. (TENX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 May 2026, 17:08.

Change

Previous filing in this sequence was filed on 08 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001230708 Primary reporting owner

STAAB THOMAS R II

Relationship: Chief Financial Officer
Address: 101 GLEN LENNOX DRIVE SUITE 300, CHAPEL HILL
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Signature date: 13 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TENX transaction

Common Stock

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 11 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TENX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +450,000
Change %
Price: $0.000000^*
Shares after: 450,000
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 450,000
Exercise price: $11.95
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock award which vests 25% ten days after the grant date, with the remainder vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries of the grant date, subject to the Reporting Person's continued employment.

Footnote F2

The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.